Haisco Pharmaceutical Group Co., Ltd.

SZSE:002653.SZ

23.19 (CNY) • At close October 26, 2023
Overview | Financials

Numbers are in millions (except for per share data and ratios) CNY.

20242023202220212020201920182017201620152014201320122011201020092008
Revenue 3,721.3493,355.073,015.2942,773.3153,329.63,937.343,426.6641,856.1611,435.6071,212.4531,210.595992.337802.069604.43581.585484.571358.762
Cost of Revenue 1,061.972972.435919.277943.4241,063.2321,348.2421,489.156657.786370.876399.415366.45268.699204.311200.946199.697140.872109.488
Gross Profit 2,659.3772,382.6352,096.0181,829.8912,266.3682,589.0991,937.5081,198.3751,064.731813.038844.145723.638597.759403.484381.888343.7249.275
Gross Profit Ratio 0.7150.710.6950.660.6810.6580.5650.6460.7420.6710.6970.7290.7450.6680.6570.7090.695
Reseach & Development Expenses 605.935516.669447.866434.13405.532235.422204.224119.198115.004157.492126.14359.70162.8532.17723.9518.8738.264
General & Administrative Expenses 785.066320.90676.11986.06978.03959.52248.58665.9252.84538.23124.26326.27833.35220.79214.61512.3295.886
Selling & Marketing Expenses 120.3821,200.3831,136.158976.3311,269.5161,713.4071,327.459754.375479.372178.183215.536144.402127.78526.68120.4919.23111.739
SG&A 905.4481,521.5921,212.2781,062.3991,347.5551,772.9291,376.046820.295532.217216.414239.799170.679161.13647.47335.10531.5617.626
Other Expenses 622.34830.842251.123215.11762.18930.532-0.931-7.176152.88910.90150.203110.467135.01883.06673.66547.66610.042
Operating Expenses 2,151.9312,069.1031,911.2671,711.6461,815.2772,038.8831,593.864975.01774.862472.616455.653306.555276.65122.03893.35877.25538.372
Operating Income 507.447313.532364.444512.257698.798546.795323.963265.961347.886405.081454.518461.296348.812287.362290.691269.359207.344
Operating Income Ratio 0.1360.0930.1210.1850.210.1390.0950.1430.2420.3340.3750.4650.4350.4750.50.5560.578
Total Other Income Expenses Net -44.497-11.0092.17-1.516-9.346-0.38-0.931-7.567151.76710.13950.03107.542131.53882.02673.17846.2439.796
Income Before Tax 462.95302.522366.614510.741689.452546.415323.032258.785500.076415.22504.547568.838480.332369.388363.869315.602217.14
Income Before Tax Ratio 0.1240.090.1220.1840.2070.1390.0940.1390.3480.3420.4170.5730.5990.6110.6260.6510.605
Income Tax Expense -3.256.96-25.03-6.84188.24771.5655.49129.68147.42943.06254.00649.61937.27157.09258.11631.88322.053
Net Income 395.455295.112391.644517.582636.621493.892333.229237.553452.724372.158450.541519.219443.061312.296305.753283.719195.087
Net Income Ratio 0.1060.0880.130.1870.1910.1250.0970.1280.3150.3070.3720.5230.5520.5170.5260.5860.544
EPS 0.350.270.360.480.60.460.310.220.410.350.420.480.410.320.320.310.21
EPS Diluted 0.350.270.360.480.60.460.310.220.410.350.420.480.410.320.320.310.21
EBITDA 750.004564.386642.776693.98851.734684.512428.607347.427322.407482.811558.786596.889502.444388.106376.577323.457224.178
EBITDA Ratio 0.2020.1680.2130.250.2560.1740.1250.1870.2250.3980.4620.6010.6260.6420.6480.6680.625